Price movement over the last 24 hours
AFLAC Incorporated vs Marqeta Inc — how do they compare? AFLAC Incorporated trades at $121.3 (market cap $61.84B), while Marqeta Inc trades at $15.56 (market cap $1.77B). The key difference: AFLAC Incorporated is far larger — about 34.9× Marqeta Inc's market cap, and AFLAC Incorporated pays a 2.01% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| AFL | MQ | |
|---|---|---|
Market Cap | $61.84B | $1.77B |
Sector | Financials | Technology |
52-Week High | $121.49 | $27.32 |
52-Week Low | $98.09 | $15.04 |
Enterprise Value | $70.50B | $1.07B |
Dividend Yield | 2.01% | — |
Signals from Pluang's Aura AI — not financial advice
Aflac (AFL) trades at $121.49, up 0.5% with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a 25.32% net income margin and 16.47% ROE, though recent Q1 2026 earnings missed expectations. Analyst consensus is mixed with 28% buy ratings and a $113.57 price target below current levels. Recent developments include strong dividend performance and upcoming Q2 2026 results announcement on August 6, 2026.
The outlook remains cautiously optimistic with solid profitability and dividend stability, but faces headwinds from recent earnings misses and premium valuation pressure. Key opportunities include continued growth in Japan and U.S. markets, while risks involve medical cost inflation and uneven revenue trends. The stock's current premium to analyst targets suggests limited near-term upside potential.
Marqeta (MQ) trades at $15.93, down 8.63% on the day, with a bullish technical outlook and mixed fundamentals. The stock recently underwent a 4:1 reverse split effective July 1, 2026. Q1 2026 earnings beat expectations with EPS of $0.08 versus -$0.0136 forecast, though Q4 2025 missed. Revenue trends show recovery from 2024's $507M to $625M in 2025, with net income narrowing losses. Analyst consensus is a $19 price target with 32% buy ratings.
The outlook hinges on execution of European expansion and credit product growth, but high P/E of 420.88 reflects significant growth expectations. Risks include ongoing profitability challenges, competitive fintech pressure, and shareholder litigation. Institutional sentiment is cautiously optimistic given the price target upside, but the stock remains speculative until sustained profitability is achieved.
Trailing returns across standard periods
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →